Meeting
2023 ASCO Genitourinary Cancers Symposium
Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
Authors
Russell Kent Pachynski
Washington University School of Medicine, St. Louis, MO
Russell Kent Pachynski , Nicholas Iannotti , Andrew Leonard Laccetti , Bradley Curtis Carthon , Kim N. Chi , Matthew Raymond Smith , Nicholas J. Vogelzang , Wilson Tu , Edmond Michael Kwan , Alexander William Wyatt , Karen Villaluna , Brett Younginger , Alessandra Cesano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04421222
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 177)
DOI
10.1200/JCO.2023.41.6_suppl.177
Abstract #
177
Poster Bd #
F14
Abstract Disclosures
Similar Posters
First Author: Johann S. De Bono
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf
Poster
2024 ASCO Genitourinary Cancers Symposium
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
First Author: Piotr Jan Wysocki
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew Leonard Laccetti